LifeMD, Inc. ( LFMD ) shares are trading higher Tuesday after the company announced it will offer access to Wegovy.

What To Know: LifeMD ( LFMD ) said it will offer access to Wegovy through Novocare Pharmacy, allowing the company to provide the weight-loss drug at a lower self-pay price of $499 per month.

The company said this offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options.

“By embedding direct access to Wegovy via NovoCare Pharmacy into our platform, we’re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD’s position as a leader in delivering comprehensive, technology-enabled obesity care,” said Justin Schreiber, Chairman and CEO of LifeMD ( LFMD ).

Related Link: Microsoft Q3 Earnings: Azure May Rise 30% – That’s Not Where ‘CTOs Are Aggressively Spending’ Analyst Warns

LFMD Price Action: At the time of writing, LifeMD ( LFMD ) shares are trading 19.8% higher at $7.31, according to data from Benzinga Pro.

Image: via Shutterstock